| Literature DB >> 27843639 |
Jennifer R Tomasone1, Melissa C Brouwers2, Marija Vukmirovic2, Eva Grunfeld3, Mary Ann O'Brien3, Robin Urquhart4, Melanie Walker5, Fiona Webster3, Margaret Fitch6.
Abstract
Coordination of patient care between primary care and oncology care providers is vital to care quality and outcomes across the cancer continuum, yet it is known to be challenging. We conducted a systematic review to evaluate current or new models of care and/or interventions aimed at improving coordination between primary care and oncology care providers for patients with adult breast and/or colorectal cancer. MEDLINE, EMBASE, CINAHL, Cochrane Library Database of Systematic Reviews, and the Centre for Reviews and Dissemination were searched for existing English language studies published between January 2000 and 15 May 2015. Systematic reviews, meta-analyses, randomised controlled trials (RCTs) and non-randomised studies were included if they evaluated a specific model/intervention that was designed to improve care coordination between primary care and oncology care providers, for any stage of the cancer continuum, for patients with adult breast and/or colorectal cancer. Two reviewers extracted data and assessed risk of bias. Twenty-two studies (5 systematic reviews, 6 RCTs and 11 non-randomised studies) were included and varied with respect to the targeted phase of the cancer continuum, type of model or intervention tested, and outcome measures. The majority of studies showed no statistically significant changes in any patient, provider or system outcomes. Owing to conceptual and methodological limitations in this field, the review is unable to provide specific conclusions about the most effective or preferred model/intervention to improve care coordination. Imprecise results that lack generalisability and definitiveness provide limited evidence to base the development of future interventions and policies. TRIAL REGISTRATION NUMBER: CRD42015025006.Entities:
Keywords: cancer care; continuity of care; coordination of care; oncology; primary care
Year: 2016 PMID: 27843639 PMCID: PMC5070279 DOI: 10.1136/esmoopen-2016-000077
Source DB: PubMed Journal: ESMO Open ISSN: 2059-7029
Figure 1PRISMA flow diagram.
AMSTAR results for included systematic reviews.
| Author | 1. Was an “a priori” design provided? | 2. Was there duplicate study selection and data extraction? | 3. Was a comprehensive literature search performed? | 4. Was the status of publication (i.e., grey literature) used as inclusion criteria? | 5. Was a list of studies (included and excluded) provided? | 6. Were the characteristics of the included studies provided? | 7. Was the scientific quality of the included studies assessed and documented? | 8. Was the scientific quality of the included studies used appropriately in formulating conclusions? | 9. Were the methods used to combine the findings of studies appropriate? | 10. Was the likelihood of publication bias assessed? | 11. Was the conflict of interest included? |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aubin | No | No | Yes | Can't Answer | No | Yes | Yes | No | N/A | N/A | No |
| Howell | No | Yes | Yes | No | No | Yes | Yes | Yes | Can't Answer | Yes | No |
| Lamb | No | No | Yes | Can't Answer | No | No | No | No | Yes | No | No |
| Lewis | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No | No | No |
| Ouwens | No | Yes | Yes | Yes | No | Yes | No | No | Yes | No | No |
Note: The “can't answer” option is chosen when the item is relevant but not described by the authors. The “not applicable” option is selected when the item is not relevant (e.g. when a meta-analysis was not attempted by the authors).
Systematic review details and study outcomes
| Author, search years, number of studies | Purpose of systematic review | Models of care examined and participants | Results | Quality of included studies | Authors’ conclusions and recommendations |
|---|---|---|---|---|---|
| Aubin | To classify, describe and evaluate the effectiveness of interventions aiming to improve patient, healthcare provider and process outcomes. | Primarily case management, shared care and interdisciplinary teams | Based on the median effect size estimates, there were no significant differences found between patients assigned to interventions and those assigned to usual care, in regards to patient health-related outcomes. | All studies were of ‘very low quality’ due to inconsistent results and high heterogeneity among studies.* | Evidence is lacking from the majority of studied outcomes; therefore, no conclusions regarding most effective interventions could be made. Future research should evaluate interventions for which improvement in continuity is the primary objective. |
| Howell | To determine the optimum organisation and care delivery structure for cancer survivorship services. | Nurse-led and primary care physician-led | Nurse-led and primary care physician models of follow-up care were equivalent for detecting recurrence. Consensus also suggested that cancer survivors may benefit from coordinated transition planning that includes the provision of survivorship care plans as a standardised part of care. | The evidence was rated as low quality, due to non-blinding of participants or outcome assessors, poor reporting of randomisation procedures, and lack of power to detect statistically significant differences between treatment groups.†‡ | Evidence is limited; however, the realignment of models of care should be identified as a health system priority, in order to meet the supportive care and surveillance needs of the survivor population. Further research is required to evaluate the efficacy of models of care in a broader population of cancer survivors with differing needs and risks. |
| Lamb | To examine the evidence on clinical, social and technological factors that affect the quality of MDT clinical decision-making. | MDTs | Failure to reach a decision at MDT discussions was found in 27–52% of cases. The majority of team decisions were made by physicians (without the inclusion of nurses) and patient preferences were not discussed. The following factors negatively affected decision-making: time pressure; excessive caseload; low attendance; poor team work; and lack of leadership. Telemedicine is effectively being used in developed countries. | Overall study quality was low to medium. The median quality score for quantitative papers was 9/18 (range 3–15) and for qualitative papers was 13/24 (range 9–14).§ | Team/social factors affect management decisions by cancer MDTs. The following may have a positive impact on team decision-making: allowing adequate time for team members to prepare for MDT meetings; making team and leadership skills training available to team-members; and considering systematic input from nursing personnel. |
| Lewis | To compare the effectiveness and cost-effectiveness of nurse-led follow-up of cancer patients, with conventional physician-led follow-up. | Nurse-led and primary care physician-led | There were no statistically significant differences in survival, recurrence or psychological morbidity. Patients with lung cancer were more satisfied with nurse-led telephone follow-up. Patients with breast cancer thought patient-initiated follow-up was convenient. No significant observations regarding cost-effectiveness were made. | Study quality ranged from poor to well-conducted; total quality score for internal validity ranged from 7 (47%) to 13 (87%). The statistical tests used in three studies were poorly-reported.¶ | Patients appeared satisfied with nurse-led follow-up. Patient-initiated or telephone follow-up could be practical alternatives to routine hospital follow-up care; however, more evaluations are required and the duration of follow-up needs to be sufficient to allow for comparison of recurrence rates. |
| Ouwens | To review integrated care interventions and their effects on the quality of cancer care. | Interventions comprising at least one of the three integrated care principles: patient-centeredness; organisation or care; and multidisciplinary care | Effective interventions to improve patient-centeredness were: providing patients with an audiotape of the consultation, and with information, and using decision aids. Effective interventions to improve the organisation of care were follow-up and case management, (particularly by nurses and one-stop clinics). | Only studies that met at least three of the five quality criteria described by the Cochrane Collaboration were included in the review.** | In order to improve integrated care for patients with cancer, a multicomponent intervention programme which focuses on patients, professionals and the organisation of care, is required. It is suggested that interventions found in this review should help to structure a future programme which would be evaluated using rigorous methods and explicit outcome measures linked to the intervention. |
*The GRADE approach was used to assess the quality of the evidence.
†The AGREE II instrument was used to assess the quality of the practice guidelines.
‡The SIGN guideline development handbook was used to assess the quality of the randomised controlled trials.
§Included studies were assessed against a quality score. Quantitative papers were scored out of a total of 18, and qualitative papers out of 24 (more detail included in online supplementary material of the original review).
¶A modified Downs and Black checklist was used to assess the quality of the evidence.
**Five methodological criteria described by the Cochrane Collaboration (ie, completeness of follow-up, reliability of outcomes, protection against contamination, baseline measurement and concealment of allocation) were used to assess the quality of the evidence.
MDT, multidisciplinary care team; RCTs, randomised controlled trials.
Cochrane risk of bias table for included randomised controlled trials.
| Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias | |
|---|---|---|---|---|---|---|---|
| Bergholdt | + | - | - | + | ? | - | ? |
| Grunfeld | + | + | + | + | + | + | + |
| Johnson | + | ? | - | ? | + | + | + |
| King | + | + | + | ? | - | ? | + |
| Wagner | + | + | - | + | + | - | + |
| Wulff | + | + | - | + | + | - | + |
Randomised controlled trial details and study outcomes
| Study author | Participants (n), type of cancer, stage of cancer care continuum | Description of study | Results |
|---|---|---|---|
| Bergholdt | n=955 patients (baseline); 612 patients (6-month follow-up); 506 patients (14-month follow-up); 776 GPs (14-month follow-up) | No statistically significant effects of the intervention were observed. Subgroup analysis of breast cancer patients showed a statistically significant improvement of satisfaction with their GP, in regards to ‘information and support’ and ‘the organisation of care’. | |
| Grunfeld | n=407 patients (baseline); 332 patients (3-month follow-up); 318 patients (6-month follow-up); 299 (12-month follow-up) | No statistically significant effects of the intervention were observed on any outcome measure, at any time point. Nine intervention and five control patients were not transferred to the PCP for follow-up due to recurrence/other reasons. After transfer to PCP, 16 control patients and 15 intervention patients visited an oncologist. Overall, over 89% of patients correctly identified their PCP as being the primary provider of follow-up care; at 12 months, significantly more intervention group patients were able to do so. | |
| Johnson | n=88 patients; 55 PCPs; 5 cancer specialists | No statistically significant differences in patients’ levels of anxiety, depression, empowerment or adverse effects of treatment were observed. No differences were detected in perceptions of care between PCPs and patients in the intervention and control groups. The majority (88%) of PCPs found the patient health records to be useful and the majority of their comments were positive. One of five cancer specialists thought the patient health record was useful and all five had concerns about the shared care model. | |
| King | n=93 patients (baseline); 61 patients (6-month follow-up) | No statistically significant differences in patients’ experienced continuity of care; some trends were observed. For example, participants in the intervention trial arms expressed less unmet needs for care than participants allocated to the control group. | |
| Wagner | n=251 patients (baseline); 242 patients (4-month follow-up); 229 patients (12-month follow-up) | There were no statistically significant differences between intervention and control groups in quality of life scores. Nurse navigator patients reported a significantly higher extent to which care actively involves patients, and reported significantly fewer problems with care (especially regarding psychosocial care, care coordination, and information). Furthermore, there were no statistically significant differences (by cancer type and intervention group) in the median cumulative costs of care, calculated from 3 months before the date of diagnosis through to 1 year postdiagnosis. | |
| Wulff | n=280 GPs (baseline); 228 GPs (30 weeks) | The use of CM was associated with a significant tendency towards more positive evaluations (particularly relating to psychological effects of the cancer, social effects of the cancer and information given to the patient by the specialists). Additionally, significantly fewer CM GPs than non-CM GPs reported having contacted the hospital regarding their patients’ care. CM did not affect the number of patient contacts with their GPs during daytime hours, but CM patients showed a tendency towards more contacts to out-of-hours GP services than non-CM patients. |
The recorded number of participants in the second column of the table represents the number that completed the study at each time point.
CM, case management; GP, general practitioner; PCP, primary care provider; RCT, randomised controlled trial; SCP, survivorship care plan.
ACROBAT-NRSI results for included non-randomised studies.
| Author | Overall risk of bias | Confounding | Selection of participants | Measurement of interventions | Departures from intended interventions | Missing data | Measurement of outcomes | Selection of the reported result |
|---|---|---|---|---|---|---|---|---|
| Aljarabah | Serious | Serious | Serious | Serious | Low | Low | Low | Low |
| Baliski | Moderate | Moderate | Low | Low | Low | Low | Low | Low |
| Blinder | Serious | Serious | Serious | Moderate | Low | Serious | Moderate | Moderate |
| Dulko | Serious | Serious | Moderate | Moderate | Low | NI | Moderate | Low |
| Hall | Serious | Serious | Serious | Low | Low | Moderate | Low | Low |
| Jefford | Serious | Serious | Moderate | Low | Low | Low | Moderate | Moderate |
| Jiwa | Serious | Serious | Serious | Moderate | Low | Low | Low | Low |
| Knowles | Serious | Serious | Moderate | Low | Low | Low | Low | Low |
| McFarlane | Moderate | Low | Moderate | Low | Low | Low | Moderate | Low |
| Sprague | Serious | Serious | Serious | Moderate | Low | Moderate | Serious | Low |
| Vanhuyse | Moderate | Moderate | Moderate | Low | Moderate | Low | Low | Low |
Non-randomised study details and study outcomes
| Study author (type of study) | Participants (n), type of cancer, stage of cancer care continuum | Description of study | Results |
|---|---|---|---|
| Aljarabah | n=3 clinical consultants (receiving GPs’ referral letters for 217 patients) | The diagnostic tests that were recommended by clinical consultants having only read GPs’ referral letters differed from those that they would have recommended having performed an in-person clinical consultation for 31% of patients. Therefore, suspected patients with colorectal cancer should be seen in a clinic by an expert before proceeding to testing. | |
| Baliski | n=97 current patients (and 100 patients from previous years) | Wait times for surgery decreased with the introduction of the programme (median of 59 vs 48 days); however, this decrease was not statistically significant. The need for MRI was found to significantly influence wait times by delaying surgery. | |
| Blinder | n=174 patients (completed at least one survey) | Of all patients who recalled receiving TPSs, 94% believed that the documents improved patient–physician communication (quality of care) and 82% believed that they improved communication between physicians (coordination of care). Participants expressed high satisfaction with TPSs. Of patients who still had their documents, 97% said they were useful (patient satisfaction). | |
| Dulko | n=17 APPs, 39 PCPs and 58 patients participated | Fifty-eight per cent of PCPs identified inadequate knowledge of cancer survivor issues as a barrier to SCP implementation and 64% identified limited access to patients as a barrier to providing follow-up care. The primary barrier to SCP completion, identified by APPs, was the time required to prepare a SCP (the average time needed was 53.9 min). | |
| Hall | n=23 patients and 5 GPs participated | Most patients and GPs had a positive outlook on shared follow-up care. Patients perceived the benefits of shared follow-up care to be improved access, convenience, travel time and continuity of care; they agreed that GPs who provide shared care should be specially trained and that shared-care must be supported by secondary care. GPs emphasised the importance of maintaining their clinical skills and receiving strong administrative support. | |
| Jefford | n=10 patients (baseline); 8 patients* | Overall, patients considered the nurse-led intervention to be appropriate, relevant, and useful. All participants agreed that nurse-led treatment sessions addressed their concerns and clarified information, and that the phone calls were informative, reassuring and allowed for continued contact with the hospital (which was deemed important). | |
| Jiwa | n=21 patients (baseline); 19 patients* | Questionnaire responses showed no statistically significant difference in physical or psychological patient outcomes. However, the majority of participants (11/17 women who had visited their GPs) reported that their condition had improved as a result of the primary care-led intervention. | |
| Knowles | n=80 patients (baseline); 60 patients* | Over the course of 1 year, nurse adherence to protocol was strict and resulted in recurrence being detected in 10 patients. Furthermore, patients’ quality of life significantly improved throughout the study period. The programme was acceptable to both patients and care providers, and the presence of nurses provided an added benefit of streamlining services and reducing the burden on outpatient resources. The assumed cost savings over a 3-year follow-up period (supposing a steady rate of 220 new patients annually) was estimated to be £28 030. | |
| McFarlane | n=950 patients, tracked for 7 years | Over the course of 7 years, 368 patients were discharged, 474 remained actively involved in the programme and 108 died. Of those who were discharged, 73% returned to the care of their GP, free of disease. Twenty patients were identified as having disease recurrence and 93 as having distant metastatic disease; of these, 65 were referred to palliative care and 28 had surgery. Overall, the clinic's detection rates of recurrent or metastatic disease were comparable to surgical consultant follow-up. | |
| Sprague | n=78 patients (baseline); 58 patients* | Ninety-one per cent of patients agreed that the SCP they received was useful, easy to understand, and that the length was appropriate. Nineteen per cent stated that they would need help in using the plan. The majority agreed that the SCP was very or critically important to understanding survivorship issues; however, only about half of all patients felt that the SCP helped them to understand the individual roles of, and the collaborative relationship between, PCPs and oncologists. | |
| Vanhuyse | n=193 patients, tracked over the course of 4 months | Transfer was deemed suitable for 43% of all patients assessed for transfer. This strategy of safely assessing follow-up patients for transfer to primary care may help in allowing oncologists to focus on primarily caring for newly diagnosed and advanced-stage patients. |
*Number of patients who completed the study.
APP, advanced practice professional; ASCO, American Society of Clinical Oncology; BC, British Columbia; GP, general practitioner; PCP, primary care provider; SCP, survivorship care plan; TPS, treatment plan and summary.